The World Health Organization (WHO) Regional Director for Europe said on Thursday that the slow pace of deployment of the COVID-19 vaccine in Europe is “unacceptable”, and he fears that these delays will prolong the pandemic and accelerate the spread of variants.
According to Hans Kluge, only 10% of the European population received the first injection, while only 4% of Europeans received the total dose of each vaccine plan.
He said in a statement: “The deployment of these vaccines is progressing slowly and unacceptably.” He insisted: “We must accelerate the movement by strengthening production, reducing the vaccination brakes and using the smallest available dose. To begin, this is a must.”
Although the infection rate has dropped to people over 80 years old (it turns out that vaccination for the elderly has been proven effective), the infection rate continues to increase in all other age groups, but the start of the vaccination campaign has been slow, making the most Young people are susceptible to contamination by the coronavirus.
Hans Kluge stated in this press release: “Accelerating vaccination is essential”, especially as worrying changes continue to spread, hospitals are under increasing pressure and the future Weekly religious holidays (Easter, Passover and Ramadan start) will lead to more travel.
Not only is Europe slower than the United Kingdom and the United States, not only did it order vaccines from laboratories last year, but also the licensing procedures for these products. Even after verification by regulatory agencies, the vaccination rate is far behind that of the United Kingdom and the United States.
In addition to limited supply, tight exports and delays in the delivery of certain vaccines, concerns about the AstraZeneca vaccine developed in cooperation with the University of Oxford have also slowed the pace of vaccination.
Although the World Health Organization and the European Medicines Agency (EMA) have reiterated the benefits of this vaccine, several cases of thromboembolic diseases have recently occurred in people receiving the vaccine, which are very rare but serious, which has caused some countries to restrict them to Used in certain people. Vaccines in Anglo-Swedish laboratories far outweigh the risk of adverse reactions.
EMA announced on Wednesday that it has not found a possible reliable link between the vaccine (now called Vaxzevria) and the appearance of atypical blood clots (thrombosis) (non-thrombotic may migrate to blocked blood vessels in certain organs) (embolism) .
The Amsterdam institution, which continues to analyze cases reported by member states, also emphasized that it has not yet identified risk factors at this stage.
France’s new vaccination schedule
In Emmanuel Macron’s speech on Wednesday night, the new vaccine strategy the government wanted was announced. Therefore, the President wants to strengthen, but most importantly, speed up the French election campaign.
- From April 16, The vaccine will be open to People between 60 and 70 years old,
- From May 15, Which will suit those 50 to 60 years old.
- From mid-June “All French people over the age of 18, “Those who want to be vaccinated” promised the President of the Republic.